Who
Harpreet S. Dhaliwal
Chief Technical Ops Officer
Company insider
Files Form 4 as: Chief Technical Ops Officer, Vaxcyte.
In numbers
- Trades disclosed
- 35
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $2.8M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 8 Nov 2021
- Last trade
- 8 Sep 2026
- Last filed
- 9 Sep 2026
Companies traded
Activity over time
1 Dec 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 8 Sep 2026filed 9 Sep 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code F | $462K7,651 at $60.36 | filing |
| 8 Sep 2026filed 9 Sep 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code F | $462K7,651 at $60.36 | filing |
| 2 Sep 2026filed 2 Sep 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code F | $41K659 at $61.58 | filing |
| 2 Sep 2026filed 2 Sep 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code F | $41K659 at $61.58 | filing |
| 31 Aug 2026filed 2 Sep 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code F | $22K361 at $60.74 | filing |
| 31 Aug 2026filed 2 Sep 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code F | $22K361 at $60.74 | filing |
| 5 Aug 2026filed 5 Aug 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code M | $421K17,000 at $24.79 | filing |
| 5 Aug 2026filed 5 Aug 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Sold | $935K17,000 at $55.00 | filing |
| 5 Aug 2026filed 5 Aug 2026 | PCVX Vaxcyteoption or derivative · Biotechnology | SEC FORM 4 Code M | —17,000 at $0.00 | filing |
| 5 Aug 2026filed 5 Aug 2026 | PCVX Vaxcyteoption or derivative · Biotechnology | SEC FORM 4 Code M | —17,000 at $0.00 | filing |
| 5 Aug 2026filed 5 Aug 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code M | $421K17,000 at $24.79 | filing |
| 5 Aug 2026filed 5 Aug 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Sold | $935K17,000 at $55.00 | filing |
| 9 Mar 2026filed 11 Mar 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code F | $36K604 at $59.32 | filing |
| 9 Mar 2026filed 11 Mar 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code F | $36K604 at $59.32 | filing |
| 2 Mar 2026filed 2 Mar 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code F | $29K465 at $61.98 | filing |
| 2 Mar 2026filed 2 Mar 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code F | $29K465 at $61.98 | filing |
| 28 Feb 2026filed 2 Mar 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code F | $18K292 at $61.98 | filing |
| 28 Feb 2026filed 2 Mar 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code F | $18K292 at $61.98 | filing |
| 26 Feb 2026filed 2 Mar 2026 | PCVX VaxcyteBiotechnology | SEC FORM 4 Code A | —53,409 at $0.00 | filing |
| 26 Feb 2026filed 2 Mar 2026 | PCVX Vaxcyteoption or derivative · Biotechnology | SEC FORM 4 Code A | —46,424 at $0.00 | filing |
News
Show Me The Money: Vaxcyte Delivers 100%+ Gains As Pneumococcal Vaccine Program AdvancesPCVX · rttnews.com · 16 Oct 2026Vaxcyte's (PCVX) Overweight Rating Reaffirmed at Cantor FitzgeraldPCVX · dailypolitical.com · 13 Oct 2026
0 headlines in the last 90 days name Harpreet S. Dhaliwal; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.